Term ends Mar 21, 2031 · High confidence
Held by Sanofi and Regeneron Pharmaceuticals, Inc.
Filed Sep 3, 2014 as application 29/501,280 · Granted Mar 21, 2017
Base term, 14 years from grant
Today
2017
2031
Clock starts
Mar 21, 2017
Mar 21, 2017
Term ends
Mar 21, 2031
Mar 21, 2031
base term
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
14 years from grant
Base term
No maintenance fees are payable on this kind of patent.
8
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its base term, 14 years from grant, with no adjustment for prosecution delay. No maintenance fees are payable on this kind of patent. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 14 years from grant | Granted Mar 21, 2017 | Mar 21, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Computed term end | The steps above, in order | Mar 21, 2031 | High confidence |
This family
| US D739,932 | In force Sep 2029 | Sep 2029 |
| US D782,033 | this patent Mar 2031 | Mar 2031 |
| US D753,291 | In force Apr 2031 | Apr 2031 |
| US D748,253 | In force Jan 2031 | Jan 2031 |
| US D789,519 | In force Jun 2032 | Jun 2032 |
| US D787,046 | In force May 2032 | May 2032 |
| US D812,740 | In force Mar 2033 | Mar 2033 |
| US D802,751 | In force Nov 2032 | Nov 2032 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 3, 2014 Reel 33659, frame 314 | Ratjen, Jochen; Wessel, Katja | Carebay Europe Limited | Assignment of Assignor's Interest |
| Sep 3, 2014 reel/frame not recorded | Carebay Europe Limited | Sanofi | Assignment of Assignor's Interest |
| Sep 3, 2014 reel/frame not recorded | Carebay Europe Limited | Regeneron Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Sep 3, 2014 Reel 33684, frame 536 | Carebay Europe Limited | Sanofi; Regeneron Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center
No maintenance fees are payable on this kind of patent, so the record carries no fee events.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Mar 2031
Term ends Mar 21, 2031. No maintenance fees are payable on this kind of patent
Citations
4
later US patents cite this one
That is below the median of design patents granted in 2017 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.